Manufacturer of Controlled Substances; Notice of Application, 48945-48946 [E6-13844]
Download as PDF
<![CDATA[
48945
Federal Register / Vol. 71, No. 162 / Tuesday, August 22, 2006 / Notices
Drug
Schedule
Gamma
hydroxybutyric
acid
(2010).
Ibogaine (7260) .............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) ......
Dimethyltryptamine (7435) ............
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ...................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine(9120) ...................
Oxycodone (9143) ........................
Hydromorphone (9150) .................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Metazocine (9240) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ....................
Fentanyl (9801) .............................
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13840 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
cprice-sewell on PROD1PC66 with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
VerDate Aug<31>2005
15:34 Aug 21, 2006
Jkt 208001
substance in Schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on March
31, 2006, Applied Science Labs,
Division of Alltech Associates Inc., 2701
Carolean Industrial Drive, State College,
Pennsylvania 16801, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in Schedule
I and II:
Schedule
Heroin (9200) ................................
Cocaine (9041) .............................
Codeine (9050) .............................
Meperidine (9230) .........................
Methadone (9250) ........................
Morphine (9300) ...........................
I
II
II
II
II
II
The company plans to import these
controlled substances for the
manufacture of reference standards.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 21, 2006.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13843 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 6, 2006,
Cambrex North Brunswick, Inc.,
Technology Centre of New Jersey, 661
Highway One, North Brunswick, NJ
08902, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
I and II:
Drug
N-Ethylamphetamine (1475) .........
Tetrahydrocannabinols (7370) ......
2,5–Dimethoxyamphetamine
(7396).
3,4–Methylenedioxyamphetamine
(7400).
4–Methoxyamphetamine (7411) ...
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Phenylacetone (8501) ...................
Hydromorphone (9150) .................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Morphine (9300) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) .............................
Schedule
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ ODL;
E:\FR\FM\22AUN1.SGM
22AUN1
48946
Federal Register / Vol. 71, No. 162 / Tuesday, August 22, 2006 / Notices
or any being sent via express mail
should be sent to DEA Headquarters,
Attention: DEA Federal Register
Representative/ODL, 2401 JeffersonDavis Highway, Alexandria, Virginia
22301; and must be filed no later than
October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13844 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
cprice-sewell on PROD1PC66 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on June 6,
2006, Cambrex North Brunswick, Inc.,
Technology Centre of New Jersey, 661
Highway One, North Brunswick, New
Jersey 08902, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Phenylacetone (8501), a
basic class of controlled substance listed
in Schedule II.
The company plans to import the
listed controlled substance to
manufacture amphetamine.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
VerDate Aug<31>2005
15:34 Aug 21, 2006
Jkt 208001
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 21, 2006.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13845 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 15, 2006,
Chemic Laboratories, Inc., 480 Neponset
Street, Building 7C, Canton,
Massachusetts 02021, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in Schedule II.
The company plans to manufacture
small quantities of a cocaine derivative
for distribution to its customers for the
purpose of research.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13850 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on June
21, 2006, Clinical Trial Services (US),
2661 Audubon Road, Audubon,
Pennsylvania 19403, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in Schedule
II:
Drug
Oxycodone (9143) ........................
Fentanyl (9801) .............................
Schedule
II
II
The company plans to import small
quantities of the listed controlled
substance in dosage form to conduct
clinical trials.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
E:\FR\FM\22AUN1.SGM
22AUN1
]]>Agencies
[Federal Register Volume 71, Number 162 (Tuesday, August 22, 2006)]
[Notices]
[Pages 48945-48946]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-13844]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 6, 2006, Cambrex North
Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One,
North Brunswick, NJ 08902, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
Schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
N-Ethylamphetamine (1475)................... I
Tetrahydrocannabinols (7370)................ I
2,5-Dimethoxyamphetamine (7396)............. I
3,4-Methylenedioxyamphetamine (7400)........ I
4-Methoxyamphetamine (7411)................. I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
Methylphenidate (1724)...................... II
Pentobarbital (2270)........................ II
Phenylacetone (8501)........................ II
Hydromorphone (9150)........................ II
Hydrocodone (9193).......................... II
Methadone (9250)............................ II
Methadone Intermediate (9254)............... II
Morphine (9300)............................. II
Sufentanil (9740)........................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative/ ODL;
[[Page 48946]]
or any being sent via express mail should be sent to DEA Headquarters,
Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-
Davis Highway, Alexandria, Virginia 22301; and must be filed no later
than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-13844 Filed 8-21-06; 8:45 am]
BILLING CODE 4410-09-P
